Evaxion secures Gates Foundation grant for polio vaccine

Evaxion A/S (EVAX) has received a grant from the Gates Foundation to develop a novel polio vaccine using its AI-Immunology™ platform, aiming to create a safer, non-live virus alternative to existing vaccines. The funding coincides with positive momentum for Evaxion, including an 80% immune response rate in its Phase 2 trial for the EVX-01 cancer vaccine and an extended cash runway to mid-2026; H.C. Wainwright maintains a Buy rating with a $14 price target. The company's AI-driven approach seeks to eliminate safety risks associated with traditional polio vaccine production, addressing the persistent global threat of the disease.

Analysis

Evaxion A/S (NASDAQ: EVAX), a clinical-stage biotechnology company with a $17.18 million market capitalization, has secured a grant from the Gates Foundation to develop a novel polio vaccine utilizing its proprietary AI-Immunology™ platform; this initiative aims to create a safer, non-live virus alternative without incurring additional operational expenditure for Evaxion. This development is supported by a 15% stock price increase over the past week, a strong balance sheet reported by InvestingPro with more cash than debt, and an extended cash runway to mid-2026 featuring $17.8 million in cash and cash equivalents as of March 2025. The company's AI platform has demonstrated clinical validation, evidenced by an 80% immune response rate in its Phase 2 trial for the EVX-01 cancer vaccine in advanced melanoma patients and promising preclinical results in controlling tumor growth. Furthermore, Evaxion's collaboration with MSD on the EVX-B2 and EVX-B3 programs is progressing, with potential option exercises and significant milestone payments anticipated later this year. Despite reporting no revenue and a net loss of $1.6 million in Q1 2025 (partially offset by financial income from derivative remeasurement), Evaxion achieved over 2,500% revenue growth in the last twelve months, and H.C. Wainwright maintains a Buy rating with a $14 price target. InvestingPro analysis also suggests EVAX may be among potentially undervalued stocks identified by its AI algorithms.

Key Decisions for Investors

• Investors should consider the positive inflection point presented by the Gates Foundation grant, which validates Evaxion's AI-Immunology™ platform and provides non-dilutive funding for its polio vaccine program, potentially enhancing the company's valuation prospects as suggested by InvestingPro's AI analysis.
• Closely monitor upcoming clinical trial readouts for the EVX-01 cancer vaccine and any announcements regarding the MSD collaboration, particularly potential option exercises and milestone payments expected later in the year, as these are key near-term catalysts.
• Evaluate the extended cash runway to mid-2026 and strong LTM revenue growth (over 2,500%) against the Q1 2025 net loss and absence of revenue, acknowledging the inherent volatility and binary risk/reward profile typical of a micro-cap, clinical-stage biotechnology firm.